Dysgeusia News and Research

RSS
Data from MK-5172 Phase II study for treatment of HCV genotype 1 infection to be presented at EASL meeting

Data from MK-5172 Phase II study for treatment of HCV genotype 1 infection to be presented at EASL meeting

New data on Merck’s VICTRELIS for chronic HCV to be presented at EASL annual meeting

New data on Merck’s VICTRELIS for chronic HCV to be presented at EASL annual meeting

GE Healthcare seeks approval to supply Optison to EU market from Oslo manufacturing facility

GE Healthcare seeks approval to supply Optison to EU market from Oslo manufacturing facility

Study projects potential impact of FDA-approved anti-obesity medications on Medicare spending

Study projects potential impact of FDA-approved anti-obesity medications on Medicare spending

Baxter files FEIBA NF BLA with FDA for prophylactic treatment of hemophilia A or B

Baxter files FEIBA NF BLA with FDA for prophylactic treatment of hemophilia A or B

Celgene announces results from REVLIMID plus VIDAZA phase II study on AML

Celgene announces results from REVLIMID plus VIDAZA phase II study on AML

Exelixis announces FDA approval of COMETRIQ for treatment of medullary thyroid cancer

Exelixis announces FDA approval of COMETRIQ for treatment of medullary thyroid cancer

European Medicines Agency accepts Exelixis’ COMETRIQ MAA for review

European Medicines Agency accepts Exelixis’ COMETRIQ MAA for review

NEJM publishes results from Celgene’s REVLIMID phase III studies on MM

NEJM publishes results from Celgene’s REVLIMID phase III studies on MM

Final results from MSD’s VICTRELIS plus PEGINTRON Phase III trial on HCV treatment-related anemia

Final results from MSD’s VICTRELIS plus PEGINTRON Phase III trial on HCV treatment-related anemia

Timely treatment with Berinert provides faster symptom relief for HAE patients

Timely treatment with Berinert provides faster symptom relief for HAE patients

Meda announces positive results from three MP29-02 studies on allergic rhinitis

Meda announces positive results from three MP29-02 studies on allergic rhinitis

FDA approves CSL Behring's Berinert for treatment of HAE attacks

FDA approves CSL Behring's Berinert for treatment of HAE attacks

Celgene reports final results from REVLIMID-rituximab combination phase II study for relapsed/refractory CLL

Celgene reports final results from REVLIMID-rituximab combination phase II study for relapsed/refractory CLL

Celgene announces data from REVLIMID Phase III study on high-risk asymptomatic smoldering MM

Celgene announces data from REVLIMID Phase III study on high-risk asymptomatic smoldering MM

Celgene reports final results from REVLIMID plus VIDAZA phase II study on higher-risk MDS

Celgene reports final results from REVLIMID plus VIDAZA phase II study on higher-risk MDS

Celgene announces interim results of REVLIMID study on CLL

Celgene announces interim results of REVLIMID study on CLL

Celgene to discontinue docetaxel and prednisone plus lenalidomide Phase III trial on CRPC

Celgene to discontinue docetaxel and prednisone plus lenalidomide Phase III trial on CRPC

Swissmedic approves REVLIMID for treatment of myelodysplastic syndromes

Swissmedic approves REVLIMID for treatment of myelodysplastic syndromes

Conference highlights advances in evidence-based integrative therapies for cancer

Conference highlights advances in evidence-based integrative therapies for cancer